Independent model study · DBTL portfolio

Protect production milestones while the experimental portfolio keeps learning

Allocate screening, confirmation, pilot and analytical capacity when programmes differ in technical-success probability, information value and due date.
Protect production milestones while the experimental portfolio keeps learning in the Acatian flowsheet workspace
One flowsheet connects assumptions, balances, equipment, time, economics and evidence.
DesignBuildMini-reactorsAssayConfirmPilotCMO handoff

Decision model

A bounded question with a complete plant consequence.

Decision

How should finite experimental and pilot capacity be allocated to maximise expected milestones without blocking contracted production work?

System boundary

Design queue through mini-bioreactor experiments, assays, confirmation, pilot run, data package and external manufacturing handoff.

Governing structure

Equations and accounting rules

01Screen capacity = reactor count × runs/day × availability
02Expected milestone value = probability-weighted accepted gates
03Scale fidelity compares kLa, P/V, tip speed, mixing and heat margin
04Queue age and repeat demand update after every gate
Scenario set

Base, alternative and stress cases

  • FIFO versus value-weighted allocation
  • Protected urgent-development capacity
  • High failure/repeat portfolio
  • Additional pilot slot or lower repeat rate

Engineering brief

Model the complete decision, not an isolated unit operation.

Ginkgo Bioworks historically disclosed a Design–Build–Test–Learn foundry loop, scale-down work and translation to external manufacturing. The current study uses that public historical pattern, not a description of present asset operation.

Every programme, priority, probability and result is synthetic. The article may mention Ginkgo in its evidence section, but the durable search intent is biotech-foundry capacity planning.

01 · Model basis

What the Acatian model needs to resolve

Inputs, mechanisms, limits and outputs remain reviewable on one declared basis.

Inputs

Data

Programme priority, due date and stage-gate criteria

Evidence

DoE size, replicates, duration and repeat rate

Plant

Reactor, pilot and analytical calendars

Basis

Scale criteria, CMO windows and milestone value

Mechanisms

Balance

Screen capacity = reactor count × runs/day × availability

Model

Expected milestone value = probability-weighted accepted gates

System

Scale fidelity compares kLa, P/V, tip speed, mixing and heat margin

Time

Queue age and repeat demand update after every gate

Constraints

Limit

Mini-reactor and pilot slots

Risk

Analytical turnaround and sample queues

Capacity

Scale-down identifiability

Gate

External CMO window and due dates

Outputs

Result

Programme throughput and expected milestones

Decision

Queue age, repeats and asset utilisation

Plant

Pilot demand and transfer timing

Value

Value of added capacity or better fidelity

02 · Acatian workflow

Build it in six controlled steps

Each step creates a reviewable object, not a hidden spreadsheet assumption.
  1. 01

    Define programmes and promotion gates.

  2. 02

    Map experiment designs and resource demand.

  3. 03

    Add uncertain outcomes and repeats.

  4. 04

    Test scale-fidelity criteria.

  5. 05

    Schedule pilot and transfer windows.

  6. 06

    Compare throughput, delay and expected value.

03 · Decisions

Questions the model should answer

Which programme receives the next slot?

Where does analytics—not fermentation—queue?

How many replicates reduce downstream risk?

Is another pilot asset economically justified?

04 · Evidence boundary

Validate before the result carries weight

Validation

Back-test stage duration, repeat rates and gate predictions against authorised portfolio history; report calibration error rather than only expected value.

Limitations

This is not a current Ginkgo operating model or a promise of technical success. Historical public disclosures must not be presented as current universal capability.

Public evidence

What the company context supports—and what it does not.

Sources establish the public process architecture. They do not reveal private operating parameters, site performance or an Acatian relationship.
  1. Ginkgo Bioworks — 2023 Annual ReportHistorical DBTL and scale-up/scale-down context.
  2. Ginkgo Bioworks — 2025 Form 10-KCurrent primary filing for company characterisation.

Frequently asked questions

Practical modelling questions

Is this the named organisation's real plant model?

No. It is an independent hypothetical Acatian study based only on the cited public process architecture. It claims no affiliation, endorsement, deployment, confidential data or actual plant performance.

Where do the numerical inputs come from?

Every input must be marked as a public fact, literature estimate, transparent engineering assumption or authorised customer input. The public article does not invent private operating values.

Can the model be calibrated to a real facility?

Yes, when the operator supplies authorised process, equipment, schedule and utility evidence and agrees the intended use, acceptance criteria and validation plan.

Related engineering guides

Continue through the connected model.

Bring one real process question

Build a model your technical team can inspect, challenge and improve.

Start with customer-owned data, explicit acceptance criteria and a clearly bounded engineering decision.